Oxford Catalysts Announces Major Lab Expansion
News Jan 30, 2008
Oxford Catalysts has announced that it is expanding its laboratory facilities and investing in additional analytical equipment in order to accelerate its catalyst development and serve its growing customer base.
The expansion, due to begin at the end of January 2008, will involve a total investment of over £1 million, and will more than double the floor space of the existing laboratory facilities.
As part of the project, Oxford Catalysts has already purchased two Amtec Spider16 high throughput screening gas phase reactor systems. These are due to be brought into operation in March and April 2008.
To supplement the rigs it already owns, it also plans to purchase three additional rigs, including a small scale Fischer-Tropsch (FT) rig, a reforming test rig, and a hydro-desulphurization test rig, along with associated analytical and catalyst preparation equipment.
In addition, Oxford Catalysts will be taking on the necessary technicians and catalyst preparation chemists needed to support the new equipment, as well as employing additional senior technology managers. In all, scientific staff numbers are expected to rise from the current 15 to around 23.
The expansion is expected to be completed by July 2008. In the meantime, Oxford Catalysts will be posting regular progress updates on its website.
Derek Atkinson, Business Development Director, Oxford Catalysts says: “Developing new catalysts can be a time consuming process, and each catalyst has to be custom-made for a particular application to suit a customer's requirements. Having this expanded lab facility will allow us to carry out the necessary testing to provide our customers with the essential information they need about a catalyst more quickly. It will also help Oxford Catalysts to develop further new and innovative catalysts at a rate that will allow us to meet demand for new applications within the clean fuels area as they continue to arise."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019